HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rave, K. Articles by Sawicki, P. T. Search for Related Content PubMed PubMed Citation Articles by Rave, K. Articles by Sawicki, P. T. Social Bookmarking                What's this?

Impact of Diabetic Nephropathy on Pharmacodynamic and Pharmacokinetic Properties of Insulin in Type 1 Diabetic Patients

¹ Profil Institute for Metabolic Research, Neuss
² Institut für Klinische Forschung und Entwicklung, Mainz
³ St. Franziskus Hospital, Cologne, Germany

ABSTRACT

OBJECTIVE—To quantify pharmacokinetic and pharmacodynamic properties of regular insulin and insulin lispro in type 1 diabetic patients with and without overt diabetic nephropathy.

RESEARCH DESIGN AND METHODS—In this double-blind, two-way cross-over, euglycemic (5 mmol/l) glucose clamp study, we investigated the metabolic response to subcutaneous injections of regular insulin and insulin lispro (0.2 U/kg) in 12 type 1 diabetic patients with overt diabetic nephropathy (proteinuria >500 mg/24 h and/or serum creatinine >1.5 mg/dl; NP group) and in a control group of 12 type 1 diabetic patients with normal renal function (DC group).

RESULTS—Peak plasma free insulin levels with insulin lispro (359 [NP] vs. 254 pmol/l [DC]) were higher and time to maximal insulin concentrations (85 [NP] vs. 99 min [DC]) shorter than with regular insulin (213 [NP] vs. 144 pmol/l [DC]; 118 [NP] vs. 153 min [DC]) in both patient groups. Overall insulin levels for regular insulin and for insulin lispro were higher in patients with overt diabetic nephropathy compared with control patients. Time to maximal metabolic effect was shorter with insulin lispro than with regular insulin in both patient groups (102 vs. 191 min [NP]; 105 vs. 172 min [DC]). The overall metabolic effect of regular insulin but not of insulin lispro was lower in patients with diabetic nephropathy than in diabetic control patients (967 vs. 1,510 mg/kg, respectively).

CONCLUSIONS—Although insulin levels are higher in patients with overt diabetic nephropathy, the metabolic response to regular insulin is reduced. Insulin lispro maintains its characteristic pharmacokinetic and pharmacodynamic properties in patients with overt diabetic nephropathy.

Abbreviations: AUC, area under the curve • GIR, glucose infusion rate • INS, insulin

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				G. Biesenbach, G. Bodlaj, H. Pieringer, and M. Sedlak Influence of residual diuresis on insulin requirement in insulin-treated type 2 diabetic patients during the first year of haemodialysis Nephrol. Dial. Transplant., January 1, 2008; 23(1): 422 - 423. [Full Text] [PDF]

				K. L. Cavanaugh Diabetes Management Issues for Patients With Chronic Kidney Disease Clin. Diabetes, July 1, 2007; 25(3): 90 - 97. [Abstract] [Full Text] [PDF]

				O. Torffvit Hyperglycaemia in diabetes: impact on nephropathy and cardiac risk Nephrol. Dial. Transplant., September 1, 2003; 18(9): 1711 - 1715. [Full Text] [PDF]

				D. E. DeWitt and D. C. Dugdale Antihyperglycemic Therapy for Patients With Renal Failure--Reply JAMA, August 27, 2003; 290(8): 1027 - 1027. [Full Text] [PDF]